Vyvgart expands to all myasthenia gravis serum types

Argenx won FDA approval May 8 for Vyvgart and Vyvgart Hytrulo to treat all adult generalized myasthenia gravis serum types—AChR-positive, MuSK, LRP4, and seronegative. The label expansion broadens eligible patient populations significantly. PDUFA date was May 10.